Ozempic cuts risk of dementia, study suggests
Weight-loss jabs can cut the risk of dementia, a study suggests.
Scientists at the University of Florida said that semaglutide in particular, whose brand names include Wegovy and Ozempic, showed promise in cutting the risk of conditions that impair memory and thought processes.
Experts said the study was encouraging and called for further research to shed light on how these drugs affect the brain.
A study by the University of Oxford in 2024 suggested that Ozempic could cut the risk of dementia by half.
Academics in the US analysed data from type 2 diabetes patients who were taking either GLP-1 receptor agonists (GLP-1RAs), which work by reducing food cravings, or sodium-glucose cotransporter-2 inhibitors (SGLT-2i) which reduce the amount of glucose the kidneys re-absorb, allowing it to pass out of the body in urine.
GLP-1RAs is a class of medication that includes semaglutide as well as the brand Rybelus, which is taken as a tablet.
Wegovy was approved to tackle weight loss on the NHS in 2023, while Ozempic and Rybelus are available as treatments for type 2 diabetes.
The study included the health records of 396,963 people over 50 from January 2014 to June 2023.
Statistically significant results
All had type 2 diabetes but no diagnosis of Alzheimer's disease and related dementias (ADRD).
Researchers compared those on GLP-1RAs, SGLT-2i and other, second-line glucose-lowering drugs.
The analysis found that 'both GLP-1RAs and SGLT2is were statistically significantly associated with decreased risk of ADRD compared with other GLDs, and no difference was observed between both drugs'.
Meanwhile, it was found that among the GLP-1RAs, 'semaglutide seems to be promising in reducing the risk of ADRD'.
'This finding is particularly intriguing given the existing research on semaglutide's neuroprotective properties,' researchers added.
Dr Leah Mursaleen, head of clinical research at Alzheimer's Research UK, said: 'We don't know yet why these medicines may be offering a protective effect and will need more research to understand how they are affecting the brain.'
She added that while the findings were 'interesting', it was important to consider if other factors might be influencing results such as overall health, income or education.
Researchers in Ireland have suggested GLP-1RAs are 'associated with a statistically significant reduction in dementia '.
Their study analysed 26 clinical trials involving almost 165,000 patients to determine if drugs such as SGLT2is and GLP-1RAs, as well as diabetes medications metformin and pioglitazone, led to a reduction in risk of dementia or cognitive impairment.
It found most drugs 'were not associated with an overall reduction in all-cause dementia' although GLP-1RAs were associated with a 'statistically significant reduction'.
Both studies have been published in the journal Jama Neurology.
Track people for longer
Dr Richard Oakley, director of research and innovation at Alzheimer's Society, said: 'Whilst both of these studies found a link between GLP-1RAs and reduced dementia risk, only one found SGLT2is, another class of diabetes drug, were also associated with a reduced risk.
'More research is needed by tracking people for longer, especially as they get older.'
Prof Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh, said the data was 'encouraging'.
'But even within these two strong studies, there are slightly conflicting results over SGLT2is, highlighting the need for further research,' she said.
'It is important to note that these drugs do have side effects and they are not guaranteed to prevent dementia.
'The studies had important limitations including a relatively short follow-up time.'
Masud Husain, a professor of neurology and cognitive neuroscience at the University of Oxford, said: 'These analyses suggest that GLP-1 receptor agonists, particularly semaglutide, might reduce the risk of developing dementia in people with type 2 diabetes.
'The wider question of whether such drugs might also be protective against dementia in people who don't have diabetes is a really intriguing one, and the focus of several ongoing clinical trials,' she added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
an hour ago
- Daily Mail
Fury grows over the NHS staff who are turning away sick private school pupils
Wes Streeting was urged to 'act swiftly' yesterday after a child was denied vital treatment because he goes to a private school. Head teachers called on the Health Secretary to step in after the eight-year-old was unable to access occupational therapy for his hypermobility syndrome. The Independent Schools Council (ISC), which represents most private schools, said pupils should receive 'equal access' to NHS care regardless of whether they are fee-paying. The intervention comes after The Mail on Sunday revealed the family of the child, who asked to remain anonymous, believe a 'two-tier system' is now at play. They say the Government's attack on private school pupils, which prompted the new VAT on fees, has 'filtered' into the NHS. However, the Department of Health said yesterday any suggestion school choice was a factor was a 'miscommunication'. According to the boy's mother, he was referred to a paediatrician at Kingston Hospital in south-west London after she noticed he was 'struggling to hold the pen well enough to write properly', along with other mobility issues. At the hospital appointment she was asked to fill in a form which asked: 'Where does your child go to school?' She was hoping to get an appointment with Richmond children's occupational therapy service that would have been the 'most important stage' of his assessment. However, days later, she received a text message saying the child had been 'declined' the crucial next appointment with occupational therapists. She then discovered the specialist unit had written to her GP, seen by the Mail, saying: 'We are unable to see this child as we do not provide a service to school-age children who attend an independent schools [sic]. We are only commissioned to provide a service to the mainstream schools.' The boy's brother had been treated for the same condition without issue several years ago. Yesterday, a spokesman for the ISC said: 'Any child coping with ill health should receive equal access to NHS services. We would urge the Government to act swiftly to ensure no child is denied care they are entitled to.' A spokesman for parent group Education Not Taxation added: 'Parents pay for these services through their taxes, and their children have the same right to these services as other children. We urge the Government to end this discrimination and ensure equal access to these services.' Yesterday, a spokesman for Kingston and Richmond NHS Foundation Trust said the boy had not been denied treatment because of his school – a prep in Kew. They said occupational therapy services are provided to all children with an education, health and care plan (EHCP), regardless of their school. EHCPs entitle children with special needs or disabilities to state-funded support and care, and are issued by councils. However, they are rationed due to funding shortages. For those without an EHCP, some state schools provide an onsite NHS occupational therapy service. The spokesman added: 'We are sorry if the wording of our correspondence has caused upset and confusion; we will amend it.' It is understood anyone without an EHCP who attends a private school would not be able to use onsite services at state schools. But there remained questions last night as to why the child was not treated at source by the NHS and instead expected to seek care at a school site. It comes after the Mail revealed other similar cases. These included the mother of an autistic girl in Somerset saying her daughter was denied access to NHS mental health services, and was told: 'If you can afford the school fees, you should pay privately.' It is also understood a child in Norfolk was refused a standing frame by the NHS because he went to private school. And young cancer patients from private schools had to pay £115 an hour for tutoring in an Edinburgh hospital's wards, while it is provided free to state school pupils by the city council.
Daily Mirror
2 hours ago
- Daily Mirror
John Whaite says 'I feel like an ageing fool' as he struggles with diagnosis
Strictly Come Dancing star John Whaite took to social media with a candid update two years after revealing he had been diagnosed with attention deficit hyperactivity disorder Former Strictly Come Dancing star John Whaite has candidly opened up on his health struggles in a new social media upload. The Bake Off star, 36, took to Instagram to reveal his thoughts on how his "superpower" can sometimes "make life confusing". John was diagnosed with ADHD in 2023 and said at the time he wished he had "known this sooner". According to the NHS, ADHD - which stands for attention deficit hyperactivity disorder - is "a condition where the brain works differently to most people". The health service explains symptoms of the diagnosis can leave people having trouble with things like concentrating and sitting still. Now, in an honest video shared to his social media page, John admitted of his condition: "Sometimes it makes life almost unbearable. I was promised I'd get older and wiser, but sometimes I feel like I'm just an ageing fool." He said in the clip: "Oh can we just talk about the reality of life with ADHD because you know a lot of the time we think we have a superpower and sometimes it can serve us very well. "It can serve us in so many ways where we can fixate on things and achieve things and create things and really do the best work or something imaginable but often that's such a pyrrhic victory because we bleed ourselves dry or we exhaust ourselves in doing it or we abandon plans or friends or family and the reality of ADHD is that it can make us believe that what we're doing in life sometimes is the exactly the righteous course of action for us." He went on: "It's the right path in spite of what people who love us might say. And then when it gets to the point where we are our interest fizzles away, the reality kicks in and we see the truth and we see the situation for what it is. "At that point we're left kind of thinking f***, I've given up so much for this. I've ignored people who love me for this. And this is really exhausting because usually the older you get the wise you get. And while that can still be true in a situation where you have ADHD I think the reality. "As you get older you don't necessarily get wiser, you just get older and when you get older and you keep making silly little mistakes people become less tolerant of those mistakes because you're meant to be older and wiser." He added that despite so much positivity surrounding the "superpower", there is also a flip side that can be "crippling and so dehumanising and annoying". John candidly confessed: "If I could chose to live life neurotypically at this point in my life, I would jump at the chance and I know that's not very pro ADHD it's not very kind of holding up the flag our community but sometimes it's just exhausting, it's horrific and sometimes I f****** hate it." John has regularly been open about his condition since his diagnosis. He has also spoke out about his mental health battle, previously suffering from bulimia and suicidal thoughts. He explained at how one point he was so low he decided to quit fame and move to Canada, where he volunteered on a farm in a bid to go back to basics and help him recover. Speaking on Steph's Packed Lunch in 2020, he said he also suffers from sexsomnia, a condition similar to night terrors and sleep walking, but instead he engages in sexual behaviour that he doesn't remember when he's awake. "You have night terrors, I have night pleasures, because I have sexsomnia," he said. "In the night, I'll be fast asleep... My boyfriend wakes up and I'll be fondling him. He's having the time of his life and I'm fast asleep." He has also admitted he was left feeling "suicidal" in the past following his Bake Off win. "I kind of felt like I'd failed. And I felt suicidal. I really really did think I was going to end it," John explained.
Scottish Sun
3 hours ago
- Scottish Sun
Number of fat jab NHS prescriptions doubles in a year as 73% of Sun readers now think about using injections
Prescriptions for Mounjaro surged to 1.1million from just 3,300 a year earlier FAT JAB BRITAIN Number of fat jab NHS prescriptions doubles in a year as 73% of Sun readers now think about using injections Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) ENGLAND has become a fat jab nation as weight loss drug prescriptions double to almost three million in a year. Demand for drugs such as Ozempic and Mounjaro show no signs of slowing, with the NHS splashing out £269million on them in 2024-25. Sign up for Scottish Sun newsletter Sign up 5 Weight loss drug prescriptions in England have doubled to almost three million in a year Credit: Getty 5 Prescriptions for Mounjaro surged to 1.1million from just 3,300 a year earlier Credit: Alamy It comes as a new Sun survey reveals 73 per cent of our readers are thinking of using them as they struggle to shift weight. Official figures show prescriptions for the big three — Ozempic, Mounjaro and Wegovy — rocketed from 1.4million in 2023-24 to 2.7million last year. The increase was driven by Mounjaro, regarded as the strongest jab, with prescriptions surging to 1.1million from just 3,300 a year earlier. Most were prescribed to people with type 2 diabetes, as the injections were designed to treat that condition, and have only recently been approved for weight loss alone. NHS figures suggest prescriptions in Wales also doubled last year, from approximately 34,000 to 70,000, and in Scotland from 40,000 to 50,000. The numbers are expected to rise again this year as the NHS introduces them through slimming clinics. More than a million people are also already buying the jabs privately. Dr Leyla Hannbeck, of the Independent Pharmacies Association, said: 'Never in my career have I seen a product with as much hype as these injections. 'The demand is absolutely huge and I expect it to keep increasing — the only way is up.' Clare Butler, 48, said the jabs also helped her mental health. Weight Loss Jabs - Pros vs Cons The mum, from Manchester, who has lost 4st 4lb, said: 'Mounjaro didn't only quieten the food noise, but it helped quieten the over-thinking, anxious thoughts that had consumed my life for so long.' She described it as, 'the best decision I've ever made for myself'. Research is revealing wide-ranging health benefits to the jabs, such as lowering risks of cancer, heart disease and dementia, yet warnings over weight loss drugs are also increasing. 5 Medics warn they must not be used in pregnancy, while trying to conceive or while breastfeeding, for fear they could lead to miscarriage or birth defects. They have also warned that rapid weight loss caused by the drugs could lead to bone loss and osteoporosis. Annual statistics from the NHS Business Services Authority show the total number of GLP-1 injections prescribed increased from 1,427,968 in the 2023-24 financial year to 2,734,499 in 2024-25. It was a 91 per cent spike — accounted for almost entirely by Mounjaro's growth. 5 Clare Butler lost 4st4lb on Mounjaro Credit: Clare Butler 5 Clare said the jabs not only helped her lose weight but improved her mental health Credit: Clare Butler The totals also included brands such as Saxenda, Ozempic and Wegovy. In the same period, the cost of prescribing rose from £137,808,297 to £269,276,366 — equal to 2.4 per cent of all NHS spending on pharmacy medicines, or £1 in every £42. The NHS said: 'We expect demand for weight loss drugs to continue to rise in the coming years.' The Department of Health added: 'We recognise the drugs' importance for treating type 2 diabetes and their exciting remit as new treatments for obesity.' Unlock even more award-winning articles as The Sun launches brand new membership programme - Sun Club.
